logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 14 of 14 Items
Showing 1 - 14 of 14 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R,  et al.
2025-03-13 • Clinical Infectious Diseases
2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article
|
Letter

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P,  et al.
2025-02-01 • IJTLD OPEN
2025-02-01 • IJTLD OPEN
Conference Material
|
Poster

12-month post-treatment outcomes of previously treated drug-resistant tuberculosis patients subsequently treated with concomitant bedaquiline and delamanid +/-carbapenem, in Mumbai, India

Chavan V, Silsarma A, Khan S, Singh P, Iyer A,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024
Journal Article
|
Research

Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study

Khan S, Silsarma A, Mahajan R, Davuluri P, Sutar N,  et al.
2024-10-12 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2024-10-12 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

BACKGROUND

Tub...

Journal Article
|
Research

Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India

Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A,  et al.
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
BACKGROUND
World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberc...
Journal Article
|
Letter

Linezolid resistance in patients with drug-resistant TB

Vengurlekar D, Walker C, Mahajan R, Dalal A, Chavan VV,  et al.
2023-07-01 • International Journal of Tuberculosis and Lung Disease
2023-07-01 • International Journal of Tuberculosis and Lung Disease
Conference Material
|
Slide Presentation

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
Bedaquiline (BDQ) and linezolid (LZD) are Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A syst...
Conference Material
|
Poster

Treatment outcomes among drug-resistant children below 10 years treated with newer drugs, in Médecins Sans Frontieres clinic in Mumbai, India

Singh SN, Singh P, Silsarma A, Iyer AS, Galindo MA,  et al.
2022-11-30 • MSF Paediatric Days 2022
2022-11-30 • MSF Paediatric Days 2022
Conference Material
|
Poster

Patient characteristics and TB treatment outcome of patients with Mono H resistance in M East ward, Mumbai, India

Mankar S, Vengurlekar D, Khan S, Silsarma A, Sutar N,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Poster

Treatment outcomes of bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Mongia H, Mansoor H, Mamnoon F, Silsarma A, Davuluri P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Slide Presentation

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
Conference Material
|
Video

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-06-07 • MSF Scientific Days International 2022
2022-06-07 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Abstract

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
In countries with a high tuberculosis (TB) burden, poor access to drug susceptibility testing is a major bottleneck in diagnosing drug-resistant (DR) TB. India is estima...